Gilead, a drugmaker, introduced a groundbreaking treatment for hepatitis C a decade ago. Since then, numerous therapies have successfully cured millions of people worldwide. However, despite this progress, the United States still struggles to combat the disease effectively.
The lack of accessibility to treatment for high-risk groups like incarcerated, uninsured, or homeless individuals hinders the country’s efforts. Only 34% of diagnosed Americans have been cured since 2013. This has prompted Dr. Carolyn Wester of the CDC to express concerns about the slow progress in eradicating hepatitis C.
To address this issue, a White House initiative spearheaded by Dr. Francis Collins aims to eliminate the disease. The proposal includes a five-year subscription contract costing $5 billion, emphasizing a national approach to treatment. The initiative also calls for a $4.3 billion campaign to raise awareness and promote treatment at various healthcare facilities.
While some states like New Mexico have implemented successful programs, challenges persist in reaching marginalized populations. Efforts to integrate treatment within existing services and collaborate with incarcerated individuals have shown promising results. However, continued funding and nationwide coordination are essential to combat hepatitis C effectively in the US.
